Skip to main content
. 2009 Dec 3;159(1):188–200. doi: 10.1111/j.1476-5381.2009.00519.x

Figure 1.

Figure 1

Effect of the 5-HT1D (BRL15572), 5-HT1B (SB216641) or the mixed 5-HT1D/1B (GR127935) receptor antagonists, mibefradil, a T-type voltage-operated calcium channel (VOCC) blocker or verapamil, an L-type VOCC blocker on the concentration–response curve for 5-HT-induced contraction. (A) Response to 5-HT in the absence (control) and presence of SB216641 (100 nM), BRL15572 (100 nM) and GR127935 (1 µM). (B) Response to 5-HT in the absence (control) and presence of SB216641 (100 µM), NNC550396 (10 µM), mibefradil (10 µM) and mibefradil combined with SB216641. (C) Response to 5-HT in the absence (control) and presence of verapamil (10 µM) and verapamil combined with SB216641. (D) Response to 5-HT in the absence (control) and presence of SB216641 (100 nM), charybdotoxin (100 nM) and charybdotoxin combined with SB216641. Results are the means ± SEM from four to five experiments (number of arteries from different animals).